Sun Pharma Advanced Research Company Ltd (SPARC)

📊 Quarterly Results (₹ Cr)

The company has moved from severe operational losses to modest revenue generation, with Q1 FY26 showing revenue growth to ₹6,358 lakhs and a significantly reduced consolidated net loss. However, operating margins remain negative (-90.7% in June 2026), reflecting the early commercialization phase of its pipeline. The sequential improvement in profitability is attributed to increased sales activity and cost management, though scale and margin expansion remain limited. The financial trajectory aligns with management’s stated focus on advancing high-growth therapeutic areas and leveraging regulatory incentives like PRVs for capital efficiency.

🔮 Management Outlook & What's Next

Management expressed confidence in future growth driven by pipeline progression in oncology and immunology, particularly highlighting monetization of a USFDA Priority Review Voucher that generated $195 million in non-dilutive capital. They emphasized strategic focus on innovation in high-value therapeutic areas and continued capital discipline. The appointment of Anil Kumar Raghavan as MD & CEO was presented as a step to strengthen execution capability. No specific forward revenue or profitability guidance was provided, but management indicated ongoing evaluation of commercial opportunities and strategic investments aligned with long-term value creation.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows a stable equity base of ₹32 lakhs with reserves fluctuating in the range of ₹-377 to ₹1,306 lakhs, indicating minimal capital base growth. Borrowings remain low at ₹556 lakhs as of March 2026, down from ₹417 lakhs in the prior period, suggesting active deleveraging or stable capital structure management. Total assets have declined significantly, from ₹336 lakhs in March 2025 to ₹322 lakhs in March 2026, reflecting asset disposals or reclassifications. The company maintains a conservative capital structure with limited debt and no major equity issuances, supporting financial stability but constrained growth reinvestment capacity.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at 65.67% across all recent quarters, indicating no dilution or stake sales. Institutional investor interest is emerging, with FII holdings increasing from 2.04% in Q4FY26 to 3.9% in Q1FY27, while DII holdings rose from 0.79% to 0.88% over the same period. The number of public shareholders has slightly increased, suggesting growing retail and institutional interest. No signs of promoter pledging or significant exits were observed, and the shareholder base remains fragmented with over 1.4 lakh shareholders, supporting liquidity and governance scrutiny.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1) Persistent negative operating margins and reliance on non-recurring or milestone-based income (e.g., PRV monetization) pose sustainability risks. 2) The company operates in a high-regulation, high-R&D pharmaceutical environment with inherent delays in clinical development and regulatory approvals. 3) Limited revenue scale and dependence on a narrow pipeline increase commercial and clinical execution risks. 4) Despite improving institutional interest, low float and high promoter holding may lead to price volatility.

📋 Recent Filings

• Announcement2026-09-25Sun Pharma Advanced Research Company Ltd (SPARC) has announced that its trading window will close on October 1, 2026, and remain shut for 48 hours aft…
• Announcement2026-08-13Sun Pharma Advanced Research Company Limited (SPARC) has formally submitted an application to stock exchanges seeking approval to reclassify its promo…
• 🟡 Board Meeting2026-08-10The board approved unaudited standalone and consolidated financial results for Q1 FY26 ending June 30, 2026, along with promoter reclassification requ…
• 🟡 deviation variation2026-08-10The Monitoring Agency Report confirms no deviation in the utilization of proceeds from SPARC's preferential issue of convertible warrants. The full ₹1…
• 🟡 Board Meeting2026-08-10SPARC held its 21st AGM on August 10, 2026, via video conference, where shareholders approved all resolutions including the appointment of Anil Kumar …
• 🔴 annual report2026-07-06Sun Pharma Advanced Research Company Limited announced its 21st Annual General Meeting will be held on Monday, August 10, 2026 at 04:30 P.M. IST via V…
• share transfer2026-07-06Sun Pharma Advanced Research Company Limited (SPARC) received confirmation certificates from its share transfer agent, MUFG Intime India Private Limit…
• Announcement2026-06-26Sun Pharma Advanced Research Company Limited announced the retirement of Ms. Shanta Gupta and Dr. Nitin Dharmadhikari effective June 30, 2026, and the…
• Announcement2026-06-25Sun Pharma Advanced Research Company Limited (SPARC) announced termination of its license agreement with CMS Bridging DMCC effective June 25, 2026, st…
• Financial Results2026-06-24Sun Pharma Advanced Research Company Limited announced that its trading window will close on July 1, 2026, ahead of unaudited quarterly results for th…

🧠 Analyst's Read

SPARC is transitioning from R&D-focused operations to a commercial-stage biopharma, supported by leadership stabilization and non-dilutive capital from PRV monetization. The next catalyst will be clinical readouts or regulatory milestones for key pipeline assets in oncology and immunology. Investors should monitor execution against development timelines and the scalability of its commercial model, particularly in international markets.

Based on filing content and financial data. Not a recommendation.